Journal of clinical and investigative dermatology最新文献

{"title":"Targeting Keloid Fibroblasts by Inhibition of Hypoxia Signaling","authors":"J. Richert-Jones, L. Ricks-Santi","doi":"10.13188/2373-1044.1000066","DOIUrl":"https://doi.org/10.13188/2373-1044.1000066","url":null,"abstract":"Keloids are persistent raised scars that are difficult to treat because attempts at removal typically results in recurrence. Keloid fibroblasts are the abnormal cell type responsible for the continuous scar protein deposition in this fibrotic skin disease that involves enhanced TGFβ activity. An effective therapy that can eliminate keloid fibroblasts and promote normal healing is needed. We examined the cellular and molecular differences between keloid and normal skin fibroblasts to identify characteristics that may be targeted for therapy. By limiting serum and/ or glucose availability, we found that keloid fibroblasts are sensitive to glucose levels but not to serum withdrawal. Treatment with 2deoxyglucose, a preclinical drug that blocks glycolytic metabolism, can reduce keloid fibroblast cell size. However, recovery occurs upon drug removal, indicating a cytostatic effect. To eliminate keloids, it would be necessary to induce cell death in order to disrupt the cycle of continuous fibrosis. Thus, we examined the role of HIF-1, a central transcription factor that regulates both glycolytic metabolism and fibrosis, to determine whether blocking its activity in keloid fibroblasts could yield a cytotoxic outcome. Using a chemical inhibitor against HIF-1, we observed a significant reduction in keloid fibroblast numbers. Although small molecule HIF-1 inhibitors have been under development for anemia and cancer therapy, their role in regulating fibrotic genes has led researchers to consider their potential use in the treatment of lung or kidney fibrosis. Since keloid disease may be considered a form of chronic skin fibrosis, reducing HIF-1 activity could provide a therapeutic strategy for keloid treatment. Avens Publishing Group Inviting Innovations Citation: Richert-Jones J, Mantel A, Ricks-Santi L, Harvey VM, Chan J. Targeting Keloid Fibroblasts by Inhibition of Hypoxia Signaling. J Clin Investigat Dermatol. 2020;8(2): 5 J Clin Investigat Dermatol 8(2): 5 (2020) Page 02 ISSN: 2373-1044 blot luminol reagent (Bio-Rad cat. no. P10026378/ P10026379, 1000 Alfred Nobel Drive Hercules, CA, USA). Primary antibodies were: phospho-SMAD2 (pSMAD2) and phospho-S6 (pS6) (Cell Signaling Technology, Inc. cat. no. 18338T and no. 4857S, respectively; 3 Trask Lane, Danvers, MA 01923, USA). Statistical analysis The results were expressed as the mean ± Standard Deviation (SD). Statistical analyses were performed using the SPSS 22.0 software, one-way ANCOVA for group comparisons or a paired T-test for pairwise comparisons. A value of p ≤ 0.05 was considered statistically significant. Results and Discussion Keloids are often compared with cancers in terms of their chronic and persistent growth. Some of these features are preserved in keloid fibroblasts (KFs); therefore, with the absence of an animal model, fibroblasts derived from keloid scars provide an important cellbased model that retains key features of keloids. Of the 10 hallmarks of cancer, keloids share 6 of them [","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48177941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter- and Intra-physician variation in quantifying actinic keratosis skin photodamage.","authors":"Benjamin Schmeusser,&nbsp;Christina Borchers,&nbsp;Jeffrey B Travers,&nbsp;Samia Borchers,&nbsp;Julian Trevino,&nbsp;Max Rubin,&nbsp;Heidi Donnelly,&nbsp;Karl Kellawan,&nbsp;Lydia Carpenter,&nbsp;Shalini Bahl,&nbsp;Craig Rohan,&nbsp;Elizabeth Muennich,&nbsp;Scott Guenthner,&nbsp;Holly Hahn,&nbsp;Ali Rkein,&nbsp;Marc Darst,&nbsp;Nico Mousdicas,&nbsp;Elizabeth Cates,&nbsp;Ulas Sunar,&nbsp;Trevor Bihl","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We investigated the variations in physician evaluation of skin photodamage based on a published photodamage scale. Of interest is the utility of a 10-level scale ranging from none and mild photodamage to actinic keratosis (AK). The dorsal forearms of 55 adult subjects with various amounts of photodamage were considered. Each forearm was independently evaluated by 15 board-certified dermatologists according to the Global Assessment Severity Scale ranging from 0 (less severe) to 9 (the most progressed stage of skin damage). Dermatologists rated the levels of photodamage based upon the photographs in blinded fashion. Results show substantial disagreement amongst the dermatologists on the severity of photodamage. Our results indicate that ratings could be more consistent if using a scale of less levels (5-levels or 3-levels). Ultimately, clinicians can use this knowledge to provide better interpretation of inter-rater evaluations and provide more reliable assessment and frequent monitoring of high-risk populations.</p>","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575200/pdf/nihms-1627493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38619393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter- and Intra-physician variation in quantifying actinic keratosis skin photodamage.","authors":"Schmeusser, J. Travers, Borchers, J. Trevino, Kellawan, L. Carpenter, S. Bahl, C. Rohan, E. Muennich, S. Guenthner, H. Hahn, Ali M Rkein, Mousdicas, E. Cates, U. Sunar","doi":"10.13188/2373-1044.1000065","DOIUrl":"https://doi.org/10.13188/2373-1044.1000065","url":null,"abstract":"We investigated the variations in physician evaluation of skin photodamage based on a published photodamage scale. Of interest is the utility of a 10-level scale ranging from none and mild photodamage to actinic keratosis (AK). The dorsal forearms of 55 adult subjects with various amounts of photodamage were considered. Each forearm was independently evaluated by 15 board-certified dermatologists according to the Global Assessment Severity Scale ranging from 0 (less severe) to 9 (the most progressed stage of skin damage). Dermatologists rated the levels of photodamage based upon the photographs in blinded fashion. Results show substantial disagreement amongst the dermatologists on the severity of photodamage. Our results indicate that ratings could be more consistent if using a scale of less levels (5-levels or 3-levels). Ultimately, clinicians can use this knowledge to provide better interpretation of inter-rater evaluations and provide more reliable assessment and frequent monitoring of high-risk populations.","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45803203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nourkrin® Woman with Marilex® Enhances Hair Growth and Appearance and Improves Hair Confidence in Women with Diffuse Hair Loss from Brazil: An Investigatorinitiated Clinical Study","authors":"M. Simoes","doi":"10.13188/2373-1044.1000063","DOIUrl":"https://doi.org/10.13188/2373-1044.1000063","url":null,"abstract":"Background: Female Pattern Hair Loss (FPHL) and Telogen Effluvium (TE) are common dermatological conditions in women, affecting half of the female population. Treating hair loss in women is more challenging since its pathogenesis is not fully understood and it commonly leads to more serious psychosocial consequences compared to hair loss in men. Recent evidence highlights the involvement of proteoglycan dysmetabolism and follicular hypoglycania as a mediating pathology. Follicular hypoglycania disturbs cellular activity and is behind the gradual deterioration of hair follicles, a condition known as Proteoglycan Follicular Atrophy (PFA). Proteoglycan Replacement Therapy (PRT) with Nourkrin® with Marilex® is a unique approach that helps to treat PFA and restore a normal hair growth cycle. Methods: We aimed to investigate the treatment satisfaction and subjective efficacy of Nourkrin® with Marilex®. To this end, 67women with moderate to severe FPHL or TE (mean age=42.73 years) were enrolled into an investigatorinitiated, subjective, cohort study carried out by practicing dermatologists in Brazil in collaboration with the World Hair Council. Study participants were randomly selected by several collaborating dermatologists and have voluntarily started a 6 month course of monotherapy with Nourkrin® Woman (600mg Marilex® per day). They were interviewed every 3 months using a semi-structured questionnaire. Results: Just after 3 months, 94.03% and 95.52% of participants reported having experienced improved hair growth and appearance, respectively; and 83.58% were more confident with their hair. All Nourkrin® users were satisfied with the results at this point and were willing to continue with the treatment. At endpoint, 94.03% of subjects experienced enhanced hair growth and 92.54% reported improved appearance of their hair. These positive changes have led 83.58% of participants to feel more confident with their hair. Overall treatment satisfaction rate with Nourkrin® therapy was 97.01%. Conclusion: Our findings indicate that women with diffuse hair loss found PRT with Nourkrin® an effective approach that stimulates hair growth and improves hair appearance. Treated patients felt more self-confident and were satisfied with Nourkrin® monotherapy. Avens Publishing Group Inviting Innovations Citation: Mattos Simoes M, Thom E, Wadstein J. Nourkrin® Woman with Marilex® Enhances Hair Growth and Appearance and Improves Hair Confidence in Women with Diffuse Hair Loss from Brazil: An Investigator-initiated Clinical Study. J Clin Investigat Dermatol. 2020;8(1): 4 J Clin Investigat Dermatol 8(1): 4 (2020) Page 02 ISSN: 2373-1044 thinning has led to the utilisation of proteoglycan-based therapies as a novel approach to hair loss. The Originator Nourkrin® with Marilex®(produced by Pharma Medico Aps, Aarhus, Denmark) uses a specific combination of bioactive proteoglycans with ‘anagen inducing’ and ‘anagen maintaining’ properties to mitigate FHG and treat PFA. This uniqu","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44216648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Lichen Planus Developing after PD-1 Inhibitor Therapy in Two Patients with Malignant Melanoma","authors":"","doi":"10.13188/2373-1044.1000056","DOIUrl":"https://doi.org/10.13188/2373-1044.1000056","url":null,"abstract":"","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45844238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Efficacy of Topical Human Breast Milk versus Hydrocortisone 1% Lotion in the Clinical Improvement of Atopic Eczema in Infants: A Non-inferiority Trial","authors":"Erica T. Rogando-Tan, E. Tianco, D. King-Ismael, Deana Dabay-Tan","doi":"10.13188/2373-1044.1000051","DOIUrl":"https://doi.org/10.13188/2373-1044.1000051","url":null,"abstract":"Increasing evidence from these published researches also support the anti-inflammatory property of HBM. A study done my Farahani et al. comparing the effect of human milk and topical hydrocortisone 1% on diaper dermatitis, showed that treatment with HBM was as effective as hydrocortisone 1% ointment in reducing severity scores in seven days [13]. This was attributed to milk components that directly exert an anti-inflammatory effect or indirectly create unfavorable environment conditions for bacterial growth by modifying the commensal flora the pH or bacterial substrates [13]. Lactation consultants have been advocates in promoting topical HBM application on sore nipples and infantile rash [13]. Mohammadzadeh et al. has shown that it is comparable to lanolin in improving sore nipples in breastfeeding women [10]. It was postulated that human milk being a source of two classes of major growth factors, transforming growth factors alpha (TGF-α) and beta (TGF-β) and the Insulin-like Growth Factors (IGF) may have roles in wound healing. TGF-α and TGF-β are involved in normal cell activities such as embryonic development, cell proliferation and tissue repair.","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43946435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrence Rate of Melanoma in Situ when Treated with Serial Disk Staged Excision: A Case Series.","authors":"Daniel Garcia,&nbsp;Robert E Eilers,&nbsp;S Brian Jiang","doi":"10.13188/2373-1044.1000037","DOIUrl":"https://doi.org/10.13188/2373-1044.1000037","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous melanoma is one of the fastest rising cancer diagnoses in recent years. Melanoma in situ (MIS) constitutes a large proportion of all diagnosed melanomas. While surgical excision is considered the standard of therapy, the literature is not clear on which surgical technique minimizes local recurrence. A common technique is serial staged excision (SSE), in which a series of mapped excisions are made according to histopathological examination of tissue. Previously published recurrence rates for SSE ranges from 0-12%, over a range of 4.7-97 months of mean follow-up.</p><p><strong>Objective: </strong>To investigate the recurrence rate of MIS when excised using a serial disk staged excision technique with tissue marked at 12 O'clock for mapping, rush permanent processing and histologic examination, 3-suture tagging for subsequent stages, and \"breadloafing\" microscopic analysis. Additionally, to determine the relationship between initial lesion size and subsequent stages of excision required for clearance, and final surgical margin.</p><p><strong>Methods: </strong>Single-institution retrospective chart review of 29 biopsy confirmed MIS lesions treated with our variant of SSE. Statistical analysis via independent t-tests.</p><p><strong>Results: </strong>No recurrences were observed with mean follow-up of 31.5 months (SD 13.9), over range of 12-58 months. Mean surgical margin of 13.1 mm (SD 5.9). A trend towards larger surgical margin was seen with increasing pre-operative lesion size.</p><p><strong>Conclusion: </strong>This method of SSE for treatment of MIS is comparable in efficacy to other SSE techniques, and may offer physicians a relatively simple, efficacious, and accessible alternative to wide local excision and Mohs micrographic surgery.</p>","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35428169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of Non-Melanoma Skin Cancers Recurring within 5 years after Mohs Micrographic Surgery: Single Institution Retrospective Chart Review.","authors":"Tina Vajdi,&nbsp;Robert Eilers,&nbsp;Shang I Brian Jiang","doi":"10.13188/2373-1044.1000036","DOIUrl":"https://doi.org/10.13188/2373-1044.1000036","url":null,"abstract":"<p><strong>Background: </strong>Mohs micrographic surgery (MMS) is used to treat certain high-risk non-melanoma skin cancers (NMSC) due to its high cure rate. However, clinical recurrences do occur in a small number of cases.</p><p><strong>Objective: </strong>We examined specific clinical characteristics associated with NMSC recurrences following MMS.</p><p><strong>Methods: </strong>We employed a retrospective chart review of the 1467 cases of NMSC that underwent MMS at UC San Diego from January 1, 2008 through December 31, 2009. A total of 356 cases were excluded due to lack of follow-up.</p><p><strong>Results: </strong>Five (0.45%) of 1111 cases developed recurrences of NMSC at the site of MMS. There were 741 cases of basal cell carcinomas (BCC); 3 were recurrences (0.40%). There were 366 cases of squamous cell carcinomas (SCC); 2 were recurrences (0.55%). Review of MMS histopathology of these recurrent tumors showed that there were no errors or difficulty with the processing or interpretation of the slides.</p><p><strong>Conclusion: </strong>Five-year recurrence rate of NMSC following MMS at our institution is below the reported average. Our retrospective chart review identified specific clinical characteristics associated with NMSC recurrence including a history of smoking, anatomical location on the cheeks, ears or nose, and a history of immunosuppression for SCCs.</p>","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35428167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seborrheic Dermatitis and Dandruff: A Comprehensive Review.","authors":"Luis J Borda,&nbsp;Tongyu C Wikramanayake","doi":"10.13188/2373-1044.1000019","DOIUrl":"https://doi.org/10.13188/2373-1044.1000019","url":null,"abstract":"<p><p>Seborrheic Dermatitis (SD) and dandruff are of a continuous spectrum of the same disease that affects the seborrheic areas of the body. Dandruff is restricted to the scalp, and involves itchy, flaking skin without visible inflammation. SD can affect the scalp as well as other seborrheic areas, and involves itchy and flaking or scaling skin, inflammation and pruritus. Various intrinsic and environmental factors, such as sebaceous secretions, skin surface fungal colonization, individual susceptibility, and interactions between these factors, all contribute to the pathogenesis of SD and dandruff. In this review, we summarize the current knowledge on SD and dandruff, including epidemiology, burden of disease, clinical presentations and diagnosis, treatment, genetic studies in humans and animal models, and predisposing factors. Genetic and biochemical studies and investigations in animal models provide further insight on the pathophysiology and strategies for better treatment.</p>","PeriodicalId":73660,"journal":{"name":"Journal of clinical and investigative dermatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.13188/2373-1044.1000019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34362029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}